Sage Therapeutics reports Q2 EPS (79c), consensus (94c)

Written by Emily J. Thompson, Senior Investment Analyst

SAGE%

Updated: Jul 30 2025

0mins

Q2 Financial Performance: Sage Therapeutics reported a Q2 revenue of $31.7 million, significantly exceeding the consensus estimate of $16.7 million, while cash and equivalents decreased from $424 million to $366 million since March 31, 2025.
Company Commitment: CEO Barry Greene highlighted the revenue growth driven by investments and execution, emphasizing their dedication to improving care for women with postpartum depression as they collaborate with Supernus on an ongoing transaction.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Sage Therapeutics reports Q2 EPS (79c), consensus (94c)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

REITs Show Strong Q1-Q3 2025 Performance with 6.2% FFO Growth

Commerce Secretary Warns Memory Chipmakers of 100% Tariffs Unless Manufacturing in U.S.

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch